|Application ||WB, E|
|Calculated MW||28393 Da|
|Antigen Region||153-182 aa|
|Other Names||3-oxo-5-alpha-steroid 4-dehydrogenase 2, 5 alpha-SR2, SR type 2, Steroid 5-alpha-reductase 2, S5AR 2, Type II 5-alpha reductase, SRD5A2|
|Target/Specificity||This SRD5A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 153-182 amino acids from the Central region of human SRD5A2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||SRD5A2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Converts testosterone (T) into 5-alpha- dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.|
|Cellular Location||Microsome membrane; Multi-pass membrane protein. Endoplasmic reticulum membrane; Multi-pass membrane protein|
|Tissue Location||Expressed in high levels in the prostate and many other androgen-sensitive tissues|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a microsomal protein expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is active at acidic pH and is sensitive to the 4-azasteroid inhibitor finasteride. Deficiencies in this gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH).
Thigpen, A.E., et al. N. Engl. J. Med. 327(17):1216-1219(1992)
Thigpen, A.E., et al. J. Clin. Invest. 90(3):799-809(1992)
Labrie, F., et al. Endocrinology 131(3):1571-1573(1992)
Andersson, S., et al. Nature 354(6349):159-161(1991)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.